Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation

Movement Disorders

Volumn 29, Issue 8, 2014, Pages 1057-1060

  Yahalom, Gilad ^a   Orlev, Yael ^a   Cohen, Oren S ^a   Kozlova, Evgenia ^a   Friedman, Eitan ^a,b   Inzelberg, Rivka ^a   Hassin Baer, Sharon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Disease progression; Genetic; LRRK2; Parkinson's disease

Indexed keywords

GLYCINE; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AGED; DISEASE COURSE; ETHNOLOGY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; JEW; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

AGED; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCINE; HUMANS; JEWS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RETROSPECTIVE STUDIES;

EID: 84904413899     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25931     Document Type: Article

References (18)

1. Inzelberg R, Schecthman E, Paleacu D, et al. Onset and progression of disease in familial and sporadic Parkinson's disease. Am J Med Genet 2004;124:255-258.
2. Hassin-Baer S, Hattori N, Cohen OS, Massarwa M, Israeli-Korn SD, Inzelberg R. Phenotype of the 202 adenine deletion in the parkin gene: 40 years of follow-up. Mov Disord 2011;26:719-722.
3. Lücking CB, Dürr A, Bonifati V, et al. French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342: 1560-1567.
4. Dachsel JC, Farrer MJ. LRRK2 and Parkinson disease. Arch Neurol 2010;67:542-547.
5. Yahalom G, Kaplan N, Vituri A, et al. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Parkinsonism Relat Disord 2012;18:1039-1041.
6. Healy DG, Falchi M, O'Sullivan SS, et al. International LRRK2 Consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
7. Greenbaum L, Israeli-Korn SD, Cohen OS, et al. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease. Parkinsonism Relat Disord 2013; 19:1053-1056.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
9. Lee JM, Koh SB, Chae SW, et al. Postural instability and cognitive dysfunction in early Parkinson's disease. Can J Neurol Sci 2012;39:473-482.
10. Kandinov B, Giladi N, Korczyn AD. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease. Parkinsonism Relat Disord. 2007;13: 243-245.
11. Sato K, Hatano T, Yamashiro K, et al. Juntendo Parkinson Study Group. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord. 2006;21:1384-1395.
12. Müller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 2000;55:888-891.
13. Roos RA, Jongen JC, van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord 1996;11:236-242.
14. Levy G, Louis ED, Cote L, et al. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 2005;62:467-472.
15. Wickremaratchi MM, Ben-Shlomo Y, Morris HR. The effect of onset age on the clinical features of Parkinson's Disease. Eur J Neurol 2009;16:450-456.
16. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011;69:193-197.
17. Alcalay RN, Mirelman A, Saunders-Pullman R, et al. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations: motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Mov Disord 2013;28:1966-1971.
18. Mirelman A, Heman T, Yasinovsky K, et al. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation. LRRK2 Ashkenazi Jewish Consortium. Mov Disord 2013;28:1683-1690